NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO
WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
AstraZeneca launches and prices bond issues of €2,200,000,000
AstraZeneca PLC, rated A3 (stable outlook) by Moody’s and A- (stable outlook) by
Standard & Poor’s, announces today the successful pricing of euro medium term
notes in an aggregate principal amount of €2,200,000,000 (the “Notes”),
consisting of three tranches:
· €500,000,000 of 5-year fixed rate notes with a coupon of 0.25%
· €900,000,000 of 8-year fixed rate notes with a coupon of 0.75%
· €800,000,000 of 12-year fixed rate notes with a coupon of 1.25%
The proceeds of the issues will be used for general corporate purposes, which
may include repayment of debt.
The Notes are being issued under the U.S.$5,000,000,000 Euro Medium Term Note
Programme of AstraZeneca PLC.
The Notes will be issued to institutional investors outside the US in accordance
with Regulation S of the U.S. Securities Act of 1933, as amended. The Notes will
be admitted to listing on the UK Listing Authority’s Official List and to
trading on the London Stock Exchange’s regulated market.
A C N Kemp
Company Secretary
9 May 2016
Notes to editors
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas –
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology – as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com
